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cling types (positive, intermediate and negative) was also different in lesions with and 
wthout plaque rupture. 
Conclusion: In the femoro-popliteal circulation, the appearance of plaque rupture is 
common (43%) and is highly associated wth positive remodeling. 
2:15 pm. 
857-2 Hospital Volume and Mortality in Acute Aortic 
Dissection: Does Low Volume Predict Worse Outcome? 
Salil J. Patel, Rajendra H. Mehta, Linda Pape, Stuart Hutchinson, Dean E. Smith, Jeanna 
V. Cooper, Pat O’Gara, Toru Suzuki, Eric M. Isselbacher, Christoph A. Nienaber, Kim A. 
Eagle, University of Michigan, Ann Arbor, MI 
Background: Acute Aortic Dissection (AAD) is associated with a very high mortality. 
Studies have shown an increased mortality at low volume centers in coronary artery 
bypass and/or valve surgery. However, to our knowledge, no studies have assessed this 
relation in AAD. To characterize whether hospital volume correlates with mortality, we 
examined outcomes data in a large cohori of patients with AAD. 
Methods: We evaluated 962 patients enrolled in the International Registry of Aortic Dis- 
section (IRAD) between l/1996 and 10/2001. Data from 15 centers in 7 countries were 
included. Linear regression analysis was performed correlating mortality and annual hos- 
pital volume. Centers were grouped and analyzed into teriiles based on AAD’volume. 
Data between low and higher volume centers was compared using a Chi-square test. 
Further adjustment for morbidity was made by means of multivariate prediction models 
for predicted death both for proximal and distal AAD, creating an overall observed versus 
expected mortality risk for each hospital. 
Results: The number of AAD cases per hospital per year ranged from 4 to 34. Overall 
hospital mortality for AAD was 25%. Mortality rates for all AAD were not significantly dif- 
ferent between lowest volume and higher volume hospitals (p=O.27). Similarly, there 
were no significant differences in death between low and high volume centers for Type A 
dissection or Type A dissections managed surgically. While there was a trend for lower 
mortality in Type B dissection in higher volume centers (p=O.O45), the confidence limits 
surrounding the point estimate were wide. 
Conclusions: AAD continues to be associated with high in-hospital mortality rates. Our 
data, reflecting cases reported over recent years, did not show a convincing difference 
between volume and outcome for AAD, despite a large population of patients collected 
by multiple centers. Risk adjustment indicated that lower volume centers did not perform 
more poorly than higher volume institutions. It may be that volume of overall heart sur- 
gery, or perhaps aortic. aortic valve, or a combination of surgical procedures proves to be 
more improtant in determining mortality in AAD, not simply the number of AAD alone. 
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857-3 The Effects of Exercise on Lower Extremity Functioning 
in Peripheral Arterial Disease Patients Without 
Intermittent Claudication: A Randomized Controlled 
Clinical Trial 
Mary M. McDermott Susan D. Tiukinhoy, Ty Gluckman, Shay Unterreiner, William H. 
Pearce, Michael H. Criqui, Kiang Liu, Jack M. Guralnik, Philip Greenland. Northwestern 
University Feinberg School of Medicine, Chicago, IL 
BACKGROUND: Most patients with lower extremity peripheral arlerial disease (PAD) do 
not have classical symptoms of intermlttent claudication (IC). We hypothesized that 
supervised exercise training would improve leg functioning in patients with PAD who do 
not have IC. METHODS: PAD subjects were identified from a non-invasive vascular lab- 
oratory at an academic medical center. Those without IC were included. Subjects were 
randomly assigned to a supervised treadmill exercise intervention vs. usual care. Exer- 
cise occurred 3 times weekly for 12 weeks for up to 60 minutes each session. The six- 
minute walk test was our primary outcome. We also measured fastest pace walkmg 
speed over 4 meters. We used intentlon to treat analyses. Of 35 enrolled, 26 completed 
baseline and follow-up testing. Of these, 54% had no exertional leg symptoms and 46% 
had exertional lea svmotoms other than IC. The table shows chanaes between baseline I , 
and follow-up. The Intervention group had a significant increase in B-minute walk pedor- 
mance between baseline and follow-uo fo=O.O2). CONCLUSION: Walkino endurance 
improved after a supervised exercise program in PAD patients without IC. If these find- 
ings are confirmed in a larger cohort, exercise may prove to have important effects on 
functional performance in PAD patients without IC. 
Changes in Lower Extremity Functianmg m Response lo Exercise 
Exercise Group (n=l6) Control group @IO) P Value 
6-minute walk (feet) 132.0 (124) 46.2 (216) 0.265 
Fast 4-meter walk (m/se@ 0.003 (0.16) -0.053 (0.14) 0.402 
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857-4 Effects of Avasimibe in Claudicants With Peripheral 
Arterial Disease 
Willlam R. Hiatt, Ellen Klepack, Mark Nehler, James Imus, Judith Regensteiner, Michael 
Criqui, University of Colorado Health Sciences Center, Denver, CO, Pfizer Global 
Research and Development, Ann Arbor, Ml 
Background: Avasimibe. an Inhibitor of acyl coenzyme A-cholesterol acyltransferase 
(ACAT), was assessed for symptomatic improvement in moderate to severe claudication. 
Methods: Patients with chronic, stable, claudicatlon symptoms secondary to PAD 
(ankle-brachial index s 0.90 at rest with a 20% reduction post-exercise) were enrolled. 
Primary endpoint, change from baseline in absolute claudication distance (ACD) com- 
pared to placebo after 52 weeks of treatment of avasimlbe 50 mg, 250 mg, or 750 mg 
daily using a graded treadmill protocol (2 mph, 2% grade every 2 minutes). 
Results: TreadmIll results are shown in the table. Avasimibe 50 mg, although not statisti- 
cally significant after adjusting for multiple comparisons, demonstrated the greatest 
improvement in ACD compared to placebo (difference = 0.76 min, p=O.O27). This finding 
was supported by change in initial claudicatlon distance (ICD) (difference = 0.5 min, 
p=O.O26) and walking distance as measured by the Walking Impairment Questionnaire 
(WIQ) (difference = 5.5%, p=O.O56). 
Conclusion: The observed increase in ACD at the 50 mg dose, although not statlstically 
significant, may suggest a symptomatic benefit with chronic oral avasimibe in claudica- 
tion. 
Least-Squares Mean Change in Time to ACD From Baseline at Week 52, Mean (SE) 
Time to ACD (minutes) Placebo Avasimibe 
50 mg 250 mg 750 mg 
N 92 90 101 90 
Change’ 0.66 (0.26) 1.42 (0.26)’ 0.96 (0.25) 0.63 (0.26) 
N=number of patients 
’ ANCOVA model 
* P=O.O27 (P<O.O245 required for statistical significance) 
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857-5 Cilostazol in Raynaud s Disease: A Double-Blind 
Placebo Controlled Clinical Trial 
San~av Rawao~alan, Dana Pfenninger, Christine Kehrer, Emily Somers, Anjan 
Chakraborti, William J. McCune, Debabrata Mukherjee, Robert D Brook, Mariana 
Kaplan, Uwersity of Michigan, Ann Arbor, Ml 
Background: Raynaud’s syndrome (RS) is characterized by recurrent episodes of 
vasospasm occuring in isolation (primary l.RS) or in association with rheumatologic 
states (secondary, 2.RS). We investigated the effect of the phosphodiesterase Ill inhibl- 
tor cllostazol I” this disorder. 
Methods: Subjects with moderate-severe RS were stratified by diagnosis (1 or 2.RS) 
and randomized to receive placebo or cilostazol 100 mglday bid for 6 weeks in a double- 
blind manner. Brachial artery vasoreactivity to assess conduit vessel function, laser Dop- 
pler fluxmetry to assess microvascular flow, and cold pressor testing (CPT) were per- 
formed at study entry and exit. Symptoms were assessed throughout the B-week 
duration using validated attack scores. 
Results: A total of 19 patients with 1 .RS and 21 patients with 2.RS matched for age, vas- 
cular risk factors, and symptom severity completed the study. Cilostazol, but not placebo, 
resulted in an increase in brachial artery diameter at 6 weeks, with a 16% and 17% 
increase in 1 .RS and 2.RS, respectively (P co.05 for both). There was no change in 
median flow-mediated dilation (FMD) (4.06 [25!“-7ti” percentile, 2.5-6.11 to -0.77 l-2.42. 
3.451) in 1 ii or Pii RS (2.23 [0.05 to 6.271 to 2.95 [1.69 to 7.41). Nitroglycerin-mediated 
dilation, microvascular flow indices, and symptom severity were unchanged in both 
cohorts. Cilostazol in l.RS, but not in 2.RS, resulted in a positive change in the slope of 
brachial responsiveness to CPT, which translated to an increase of 0.32 mmlmin com- 
pared with placebo (P = 0.002). Cilostazol treatment remained significantly associated 
with increased brachial artery diameter when controlled for body mass index, age, cho- 
lesterol, triglycerides, cholesterol/high-density lipoprotein ratio, and systolic blood pres- 
sure (P= 0.018). 
Conclusion: Cilostazol increases conduit vessel diameter in RS. There was a favorable 
Impact on conduit vessel responsiveness to cold in 1 .RS without impacting microvascular 
flow or symptoms at 6 weeks. A longer duration of treatment or higher doses may be 
required to see a benefit in these parameters in RS. These results provide Important 
Insights for designing future pharmacotherapeutic interventions in RS. 
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857-6 A Prospective Case-Control Study of Tobacco 
Dependence in Thromboangiitis Obliterans (Buerger s 
Disease) 
Leslie T. Cooper, Stavonnie S. Henderson, Kenneth P. Offord. Tak Sun Tse, David R. 
Holmes, Richard D. Hurt, Mayo Clinic and Foundation, Rochester, MN 
Background: Thromboangiitis Obliterans (TAO) is often cited as an extreme phenotype of 
vasculopathy and tobacco dependence. Although tobacco exposure IS essential to pro- 
gression of arterial ischemia in TAO, expert opinion differs regarding the degree of 
tobacco dependence in this population. We designed a prospective, case-control study 
